Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

• Principais autores: Alessandra M. Campos-Staffico (Autor), Michael P. Dorsch (Autor), Geoffrey D. Barnes (Autor), Hao-Jie Zhu (Autor), Nita A. Limdi (Autor), Jasmine A. Luzum (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) are the first-line guideline-recommended therapy since they are as effective and overall safer than warfarin in pre...